Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of blood cancer called diffuse large B-cell lymphoma, confirmed by laboratory testing of tissue samples, where the cancer cells test positive for a protein called CD20.
• People whose lymphoma has been confirmed by a pathologist to be a "double-expressor" type, meaning the cancer cells show high levels of two specific proteins (MYC at 40% or above, and BCL2 at 50% or above).
• People whose cancer showed a complete response (no detectable cancer) after their first course of treatment.
• People aged 18 to 80 years.
• People whose general physical health and ability to carry out daily activities falls within a certain range, as assessed using a standard medical scale (confirm with trial site).
• People with no history of any other cancer, either in the past or currently.
• People whose lymphoma is rated above a score of 1 on a standard risk-assessment tool called the International Prognostic Index (confirm with trial site).
• People who test positive for a specific marker in the blood called ctDNA MRD at the time of enrolling in the trial, which indicates a small amount of cancer-related material may still be present.
• People expected to live for at least 6 months, based on the treating doctor's assessment.
• People who provide written consent before any trial procedures begin.

Who may not be able to join:

• People whose cancer did not achieve a complete response after their first course of treatment.
• People who have previously had an organ transplant.
• People with uncontrolled blood clotting problems or active bleeding.
• People with uncontrolled heart or blood vessel disease, including reduced heart pumping function (below 50%), certain connective tissue conditions, or serious active infections.
• People who had major surgery within 6 weeks before joining the trial.
• People whose routine blood test results — for reasons unrelated to their lymphoma — fall outside acceptable ranges, including low white blood cell counts, low platelet counts, or abnormal liver or kidney function levels (confirm with trial site for specific thresholds).
• People with active hepatitis B infection that does not meet specific virus level requirements set by the trial (people who test positive for certain hepatitis B markers will need additional testing to determine whether they meet the trial's requirements).
• People with HIV infection.
• People currently receiving any cancer treatment for lymphoma or another cancer.
• People with drug or alcohol dependence that may affect how trial results are assessed.
• People with a psychiatric illness or any condition that would make it difficult to follow the trial's requirements.
• People who need to take certain medications that strongly affect how the body processes drugs (called CYP3A inhibitors or inducers), or who have taken these medications within 7 days — or within a set number of half-lives — before the first trial dose (confirm with trial site).
• People who cannot swallow capsules, or who have significant digestive system conditions that may affect how the body absorbs medication, such as malabsorption conditions, previous weight-loss surgery, inflammatory bowel disease, or bowel blockage.
• People with any other serious uncontrolled medical condition that the trial doctor believes could affect safety, drug absorption, or place the person at unacceptable risk.

Important: Always verify eligibility with the trial site directly before applying.